No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
CELU240816C10000
- 0.85
- 0.000.00%
15min DelayTrading Mar 25 13:18 ET
0.00High0.00Low
0.00Open0.85Pre Close0 Volume0 Open Interest10.00Strike Price0.00Turnover582.44%IV261.67%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier24DDays to Expiry0.85Extrinsic Value100Contract SizeAmericanOptions Type0.4845Delta0.0879Gamma3.53Leverage Ratio-0.0372Theta0.0004Rho1.71Eff Leverage0.0031Vega
Intraday
- 5D
- Daily
News
Express News | Celularity Presents Data On T-Cell Therapy Platform At ASCO Annual Meeting; PT-CD16VS Shows Potent Activity And Potential For Combination With Monoclonal Antibodies To Target Multiple Cancers
Express News | Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing
Express News | Celularity Granted European Patent EP3957315 For Treatment Of Diabetic Peripheral Neuropathy Using Placental Cells
Celularity Data Published in Journal for ImmunoTherapy of Cancer Reveals Benefits of Placental Circulating T Cells for CAR-T Therapy
Celularity Inc. to Host Investor and Analyst Research & Development Day
Express News | Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing
Comments
$Celularity(CELU.US$ Celularity Presents Data On T-Cell Therapy Platform At ASCO Annual Meeting; PT-CD16VS Shows Potent Activity And Potential For Combination With Monoclonal Antibodies To Target Multiple Cancers
1
$Celularity(CELU.US$ Celularity Granted European Patent EP3957315 For Treatment Of Diabetic Peripheral Neuropathy Using Placental Cells
1
2
$Celularity(CELU.US$
NEWS
Celularity Data Published in Journal for ImmunoTherapy of Cancer Reveals Benefits of Placental Circulating T Cells for CAR-T Therapy
Celularity (NASDAQ: CELU) has announced that data published in the Journal for ImmunoTherapy of Cancer highlights the benefits of its placental-derived T-Cell platform for CAR-T therapies. The study revealed that CAR-T cells from Celularity's platform demonstrated greater persistence, resistance to exhaustion, and efficacy compared to tho...
NEWS
Celularity Data Published in Journal for ImmunoTherapy of Cancer Reveals Benefits of Placental Circulating T Cells for CAR-T Therapy
Celularity (NASDAQ: CELU) has announced that data published in the Journal for ImmunoTherapy of Cancer highlights the benefits of its placental-derived T-Cell platform for CAR-T therapies. The study revealed that CAR-T cells from Celularity's platform demonstrated greater persistence, resistance to exhaustion, and efficacy compared to tho...
$Celularity(CELU.US$ Celularity To Present Data Showing Senescent Cell Elimination By Off-The-Shelf Natural Killer Cells Derived From Human Placental Cells
Benzinga· 2 mins ago
Benzinga· 2 mins ago
1
$Celularity(CELU.US$ Celularity Receives Healthcare Common Procedure Coding System Q Code Approval From The U.S. Centers For Medicare & Medicaid Services For Biovance 3L
Benzinga· 1 min ago
Benzinga· 1 min ago
Read more